Integra LifeSciences Holdings Corp. Rating Increased to Neutral at Merrill Lynch (IART)
Integra LifeSciences Holdings Corp. (NASDAQ:IART) was upgraded by Merrill Lynch to a “neutral” rating in a research note issued on Wednesday, American Banking and Market News reports.
Several other analysts have also recently commented on the stock. Analysts at Bank of America Corp. upgraded shares of Integra LifeSciences Holdings Corp. from an “underperform” rating to a “neutral” rating in a research note to investors on Wednesday. Separately, analysts at Morgan Stanley upgraded shares of Integra LifeSciences Holdings Corp. from an “underweight” rating to an “equal weight” rating in a research note to investors on Monday, November 11th. They now have a $40.00 price target on the stock. Finally, analysts at Morgan Stanley reiterated a “sell” rating on shares of Integra LifeSciences Holdings Corp. in a research note to investors on Sunday, November 3rd. They now have a $40.00 price target on the stock. Ten equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $46.18.
Shares of Integra LifeSciences Holdings Corp. (NASDAQ:IART) traded up 1.77% on Wednesday, hitting $49.46. 398,827 shares of the company’s stock traded hands. Integra LifeSciences Holdings Corp. has a 1-year low of $30.87 and a 1-year high of $49.24. The stock has a 50-day moving average of $46.6 and a 200-day moving average of $42.03. The company’s market cap is $1.390 billion.
Integra LifeSciences Holdings Corp. (NASDAQ:IART) last released its earnings data on Monday, October 28th. The company reported $0.72 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.70 by $0.02. The company had revenue of $213.20 million for the quarter, compared to the consensus estimate of $214.05 million. During the same quarter in the prior year, the company posted $0.85 earnings per share. The company’s quarterly revenue was up 1.5% on a year-over-year basis. On average, analysts predict that Integra LifeSciences Holdings Corp. will post $2.53 earnings per share for the current fiscal year.
Integra LifeSciences Holdings Corporation (NASDAQ:IART) is an integrated medical technology company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.